Thai PM sorry for 19 vaccination delays



BANGKOK, June 15 (Reuters) - Thailand's prime minister apologised and took the blame on Tuesday for coronavirus vaccination delays, while thousands of private companies and public organisations raced to secure doses imported by a royal-backed academy.

Prime Minister Prayuth Chan-ocha said holdups were caused by supply and distribution issues, after some hospitals in Bangkok were forced to postpone scheduled inoculations this week.

"I apologise for the problem and would like to take full responsibility for solving it," Prayuth told reporters.

"We will try to manage this better going forward."

So far 4.76 million of Thailand's more than 66 million people have received at least one dose of a COVID-19 vaccine.

Thailand's strategy relies heavily on a local firm owned by its king, which is making the AstraZeneca AZN.L vaccine for distribution in Southeast Asia, but has had to delay and downsize some deliveries.

Thailand has been scrambling to procure more vaccines and diversify brands in recent months.

Nearly 7,000 organisations, including private firms and provincial organisations, are seeking "alternative vaccines" from an academy chaired by the king's youngest sister, Princess Chulabhorn, the academy said.

It last week said 1 million doses of Sinopharm's vaccine should be available from June 20.

Opas Karnkawinpong of the Department of Disease Control said he expected 6.5 million doses of coronavirus vaccine would be distributed this month in total, of which 3.5 million had already been delivered.
Reporting by Panarat Thepgumpanat; Writing by Patpicha Tanakasempipat; Editing by Martin Petty

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示: 您的資金存在風險。杠杆商品可能不適合所有客戶。 請詳細閱讀我們的風險聲明